KAMPALA – In its recently unveiled Annual Report for FY 2022/23, the National Drug Authority (NDA) paints a vivid picture of triumphs and challenges in Uganda’s healthcare landscape. From licensing over 14,700 drug outlets and recording double the anticipated reports on adverse drug reactions to commissioning state-of-the-art laboratories and promoting local pharmaceutical manufacturing, the NDA has showcased resilience and innovation in ensuring the safety, efficacy, and quality of healthcare products. While celebrating these accomplishments, the report also addresses persistent challenges and offers a strategic vision for sustainable health regulation in the years ahead.
As Uganda continues to grapple with increasing healthcare demands, the NDA’s role remains pivotal in safeguarding the public from substandard drugs and medical products while promoting sustainable access to quality healthcare solutions. The report offers an in-depth look at the strategic roadmap for the future, providing a lens into the progress of healthcare regulation in Uganda.
Service Delivery and Strategic Implementation
In an ambitious push for greater efficiency, the NDA reported a 95 percent performance rate at impact and outcome levels, supported by an impressive 92 percent activity implementation efficiency. The establishment of a regional office in Soroti marked a significant step toward decentralizing operations and enhancing access to services across the country. Transitioning to automated systems, such as the Integrated Regulatory Information Management System (IRIMS), further streamlined regulatory processes, improving efficiency and transparency in the oversight of pharmaceuticals and medical devices.
Ensuring Regulatory Compliance through Licensing and Inspections
The NDA licensed over 14,700 drug outlets nationwide, including retail and wholesale pharmacies, drug shops, and medical device stores. This extensive regulatory oversight not only improved access to quality healthcare products but also minimized the risk of counterfeit drugs infiltrating the market. Additionally, the authority inspected and approved 35 local manufacturers, ranging from pharmaceutical and herbal medicine producers to repackaging facilities. Internationally, 155 foreign manufacturers underwent rigorous inspections to ensure compliance with Good Manufacturing Practices (GMP). These efforts underscore the NDA’s focus on maintaining high standards for drug safety and efficacy, both locally and globally.
Advancing Product Safety and Pharmacovigilance
In a year marked by increased vigilance, the NDA recorded over 5,000 adverse drug reactions (ADR) and adverse events following immunization (AEFI) reports—more than double its target. Investigations into these reports, along with 1,344 post-market surveillance tests, provided critical data to mitigate risks and ensure the quality and safety of healthcare products available in Uganda. These activities reflect a robust pharmacovigilance system, safeguarding public health through proactive interventions and enhanced oversight.
Innovation in Clinical Trials and Product Registration
The NDA demonstrated its commitment to fostering innovation by reviewing 177 clinical trial applications, conducting Good Clinical Practice inspections, and supporting the registration of over 5,500 pharmaceutical products. These included 482 locally manufactured drugs and 300 herbal medicines, emphasizing the authority’s dedication to promoting local production while adhering to global safety and efficacy standards. By facilitating ethical and scientifically sound research, the NDA has laid a solid foundation for advancements in drug development and public health solutions.
Elevating Laboratory Services
The NDA achieved a pharmaceutical product quality compliance rate of 93 percent, surpassing the previous year’s performance. This achievement was bolstered by the operation of ISO-accredited laboratories, which conducted nearly 2,000 quality control tests. The commissioning of a pharmaceutical microbiology laboratory further expanded the NDA’s testing capabilities, addressing emerging health needs such as the quality assurance of hand sanitizers, herbal products, and medical devices. These strides reinforce Uganda’s position as a leader in pharmaceutical quality assurance within the region.
Governance, Stakeholder Engagement, and Sustainability
In addition to its technical achievements, the NDA prioritized governance and social responsibility. Environmental sustainability initiatives included the safe disposal of 3.4 million kilograms of pharmaceutical waste, a critical step in reducing environmental hazards. The authority also engaged stakeholders through 538 meetings and educational campaigns, fostering collaboration with healthcare professionals, manufacturers, and the public. Internally, the NDA enhanced its workforce by increasing staffing levels and promoting gender diversity, with women making up 37% of the workforce.
Challenges and the Way Forward
While the NDA recorded numerous successes, it also faced challenges, such as low response rates in stakeholder engagements and difficulties in acquiring targeted samples for post-market surveillance. To address these gaps, the authority recommends further automation of regulatory processes, adopting risk-based approaches for market surveillance, and strengthening engagement strategies to enhance collaboration with stakeholders.
A Vision for the Future
Looking ahead, the NDA is poised to align its next five-year strategic plan with Uganda’s National Development Plan IV, focusing on enacting new regulatory laws and enhancing sustainability. This forward-thinking approach will ensure the authority continues to address emerging public health challenges while fostering innovation and excellence in healthcare regulation.
The National Drug Authority’s Annual Report for FY 2022/23 is a testament to its unwavering dedication to safeguarding public health in Uganda. By setting higher standards for regulatory oversight, product safety, and stakeholder engagement, the NDA is not only transforming healthcare delivery but also building public trust in the country’s healthcare system. With its strategic outlook firmly in place, the NDA remains a cornerstone of Uganda’s journey toward improved health outcomes and sustainable development.
